まとめ抗菌薬　表とリストで一覧・比較できる、特徴と使い方

出版社： 羊土社
著者：
発行日： 2024-03-15
分野： 臨床医学：内科  >  感染症/AIDS
ISBN： 9784758124133
電子書籍版： 2024-03-15 （第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

3,960 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

人気X（旧Twitter）アカウント「新米ID」を運営する著者と，ヒットメーカー佐藤弘明先生がタッグを組んだ，要点がひと目でわかる抗菌薬の入門書！細菌・抗菌薬・感染症の3つの観点から知識が整理できる！

目次

  • 第１章　感染症診療の原則まとめてみました
    　原則(1) 患者背景を考えよ～患者を知る～
    　原則(2) 感染源を同定せよ～感染巣はどこ？～
    　原則(3) 原因菌を突き詰めよ～グラム染色と血液培養は重要～
    　原則(4) ドレナージを検討せよ～原因菌を排除せよ～
    　原則(5) 投与時間と投与量を決めよ～抗菌薬の効果が最大となるよう投与する～
    　原則(6) 治療期間を決めよ
    　　　　　■ 治療中のアセスメント～臓器特異的な症状や細菌学的検査に着目せよ～
    　　　　　■ 抗菌薬が効かない５つの問題
    　　　　　■ 抗菌薬の最適化～definitive therapyとde-escalation

    第２章　臨床的に重要な細菌まとめてみました
    　1　グラム陽性球菌（GPC）
    　2　グラム陽性桿菌（GPR）
    　3　グラム陰性球菌（GNC）
    　4　グラム陰性桿菌（GNR）

    第３章　抗菌薬の使い方まとめてみました
    　1　ペニシリン系
    　　　1 ペニシリンG（PCG）／2 アンピシリン（ABPC）／3 アモキシシリン（AMPC）／4 アンピシリン/
    　　　5 スルバクタム（ABPC/SBT）／5 アモキシシリン/クラブラン酸（AMPC/CVA）／
    　　　6 ピペラシリン（PIPC）／7 ピペラシリン/タゾバクタム（PIPC/TAZ）
    　　　[Column] ESBLとAmpCをもう少し詳しく
    　2　セフェム系
    　　　1 セファゾリン（CEZ）／2 セファレキシン（CEX）／3 セフォチアム（CTM）／
    　　　4 セファクロル（CCL）／5 セフメタゾール（CMZ）／6 セフトリアキソン（CTRX）／
    　　　7 セフォタキシム（CTX）／8 セフタジジム（CAZ）／9 セフトロザン/タゾバクタム（CTLZ/TAZ）／
    　　　10 セフェピム（CFPM）
    　3　カルバペネム系
    　　　1 メロペネム（MEPM）
    　4　アミノグリコシド系
    　　　1 ゲンタマイシン（GM）／2 トブラマイシン（TOB）／3 アミカシン（AMK）
    　5　キノロン系
    　　　1 シプロフロキサシン（CPFX）／2 レボフロキサシン（LVFX）／3 モキシフロキサシン（MFLX）
    　6　マクロライド系
    　　　1 エリスロマイシン（EM）／2 クラリスロマイシン（CAM）／3 アジスロマイシン（AZM）
    　7　リンコマイシン系
    　　　1 クリンダマイシン（CLDM）
    　　　[Column] 市中と院内で性質の異なるMRSA／クリンダマイシンのDテストについて
    　8　テトラサイクリン系
    　　　1 ドキシサイクリン（DOXY）／2 ミノサイクリン（MINO）
    　9　ニトロイミダゾール系
    　　　1 メトロニダゾール（MNZ）
    　10　ST合剤（SMX/TMP）
    　抗MRSA薬
    　11　グリコペプチド系
    　　　1 バンコマイシン（VCM）／2 テイコプラニン（TEIC）
    　12　オキサゾリジノン系
    　　　1 リネゾリド（LZD）／2 テジゾリド（TZD）
    　13　リポペプチド系
    　　　1 ダプトマイシン（DAP）

    第４章　抗真菌薬の使い方まとめてみました
    　1　アゾール系
    　　　1 フルコナゾール（FLCZ）／2 イトラコナゾール（ITCZ）／3 ボリコナゾール（VRCZ）／
    　　　4 ポサコナゾール（PSCZ）
    　2　キャンディン系
    　　　1 ミカファンギン（MCFG）／2 カスポファンギン（CPFG）
    　3　ポリエン系
    　　　1 リポソーマルアムホテリシンB（L-AMB）

    第５章　感染症ごとの使い方、考え方
    　1 細菌性髄膜炎／2 急性副鼻腔炎／3 急性中耳炎／4 急性扁桃炎／5 市中肺炎／6 院内肺炎／
    　7 急性胆嚢炎／8 急性腸炎／9 急性腎盂腎炎／10 性感染症（淋菌性尿道炎）／11 蜂窩織炎／
    　12 壊死性筋膜炎／13 関節炎／14感染性心内膜炎／15 カテーテル関連血流感染症

    付 録
    　付録1　主な細菌感染症の治療期間
    　付録2　腎機能に合わせた投与量
    　付録3　妊婦と授乳婦への投与

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 感染症診療の原則まとめてみました

P.26 掲載の参考文献
1) Hageman JC, et al:Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis, 12:894-899, 2006
PubMed
2) Paprocka P, et al:Pseudomonas aeruginosa Infections in Cancer Patients. Pathogens, 11:679, 2022
PubMed
3) Leone G & Pizzigallo E:Bacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic Diseases. Mediterr J Hematol Infect Dis, 7:e2015057, 2015
PubMed
4) 「抗菌薬適正使用生涯教育テキスト 第3版」(日本化学療法学会, 抗菌化学療法認定医認定制度審議委員会/編), 日本化学療法学会, 2020
 
5) Bai AD & Morris AM:Management of Staphylococcus aureus bacteremia in adults. CMAJ, 191:E967, 2019
PubMed
6) Dermawan JKT, et al:Candida pneumonia with severe clinical course, recovery with antifungal therapy and unusual pathologic findings:A case report. Medicine (Baltimore), 97:e9650, 2018
PubMed
7) Chan KE, et al:Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol, 23:1551-1559, 2012
PubMed

第2章 臨床的に重要な細菌まとめてみました

P.43 掲載の参考文献
1) Heilbronner S & Foster TJ:Staphylococcus lugdunensis:a Skin Commensal with Invasive Pathogenic Potential. Clin Microbiol Rev, 34:2021
PubMed
2) Lawal OU, et al:Foodborne Origin and Local and Global Spread of Staphylococcus saprophyticus Causing Human Urinary Tract Infections. Emerg Infect Dis, 27:880-893, 2021
PubMed
3) Koruga N, et al:Aggressive Pyogenic Spondylitis Caused by S. constellatus:A Case Report. Diagnostics (Basel), 12:2686, 2022
PubMed
4) Takamura N, et al:Infective endocarditis caused by Streptococcus gallolyticus subspecies pasteurianus and colon cancer. BMJ Case Rep, 2014:2014
PubMed
5) Theilacker C, et al:Overwhelming Postsplenectomy Infection:A Prospective Multicenter Cohort Study. Clin Infect Dis, 62:871-878, 2016
PubMed
6) Rodrigo C, et al:Pharmacological management of tetanus:an evidence-based review. Crit Care, 18:217, 2014
PubMed
7) Yamamuro R, et al:Clinical Characteristics of Corynebacterium Bacteremia Caused by Different Species, Japan, 2014-2020. Emerg Infect Dis, 27:2981-2987, 2021
PubMed
8) Salem N, et al:Corynebacterium urealyticum:a comprehensive review of an understated organism. Infect Drug Resist, 8:129-145, 2015
PubMed
9) Eke UA, et al:Campylobacter fetus aortitis in a patient with HIV. IDCases, 25:e01169, 2021
 

第3章 抗菌薬の使い方まとめてみました

P.65 掲載の参考文献
1) Radolf JD, et al:Syphilis (Treponema pallidum). [Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed] (Bennett JE, et al), p2887, Elsevier, 2019
 
2) O'Callaghan K, et al:Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU:A retrospective cohort study. Int J Antimicrob Agents, 56:106010, 2020
PubMed
P.93 掲載の参考文献
1) Paterson DL & Doi Y:Chapter 21 Cefaclor, Cefprozil, and Loracarbef. [Kucers' The use of antibiotics, 7th ed] (Grayson ML, ed), pp376-382, CRC Press, 2018
 
2) Peterson SC, et al:Combination of Ceftriaxone and Ampicillin for the Treatment of Enterococcal Endocarditis:A Qualitative Systematic Review. Ann Pharmacother, 51:496-503, 2017
PubMed
3) Bai AD, et al:Ceftriaxone and the Risk of Ventricular Arrhythmia, Cardiac Arrest, and Death Among Patients Receiving Lansoprazole. JAMA Netw Open, 6:e2339893, 2023
PubMed
4) Doi Y:Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin Infect Dis, 69:S565-S575, 2019
PubMed
5) Snydman DR, et al:Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother, 58:1218-1223, 2014
PubMed
6) Fugate JE, et al:Cefepime neurotoxicity in the intensive care unit:a cause of severe, underappreciated encephalopathy. Crit Care, 17:R264, 2013
PubMed
P.99 掲載の参考文献
1) Wilson APR:Sparing carbapenem usage. J Antimicrob Chemother, 72:2410-2417, 2017
PubMed
P.111 掲載の参考文献
1) 「抗菌薬TDM臨床実践ガイドライン2022」(抗菌薬TDMガイドライン作成委員会/TDMガイドライン策定委員会抗菌薬小委員会/編), 日本化学療法学会/日本TDM学会, 2022
 
P.123 掲載の参考文献
1) Luangtongkum T, et al:Antibiotic resistance in Campylobacter:emergence, transmission and persistence. Future Microbiol, 4:189-200, 2009
PubMed
2) FDA Drug Safety Communication:FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections;warns about disabling side effects that can occur together. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain
 
3) Hu T, et al:Dose- and time-dependent manners of moxifloxacin induced liver injury by targeted metabolomics study. Front Pharmacol, 13:994821, 2022
PubMed
4) [LiverTox:Clinical and Research Information on Drug-Induced Liver Injury] (National Institute of Diabetes and Digestive and Kidney Diseases), 2012 https://www.ncbi.nlm.nih.gov/books/NBK547852/
 
P.134 掲載の参考文献
1) Kudoh S, et al:Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med, 157:1829-1832, 1998
PubMed
2) Matzneller P, et al:Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother, 57:1736-1742, 2013
PubMed
P.138 掲載の参考文献
1) 「MRSA感染症の治療ガイドライン 改訂版2019」(MRSA感染症の治療ガイドライン作成委員会/編), 日本化学療法学会, 日本感染症学会, 2019
 
P.141 掲載の参考文献
1) Campbell AJ, et al:Adjunctive protein synthesis inhibitor antibiotics for toxin suppression in Staphylococcus aureus infections:a systematic appraisal. J Antimicrob Chemother, 74:1-5, 2019
 
2) Cosgrove SE & Fowler VG Jr:Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis, 46 Suppl 5:S386-S393, 2008
 
3) Johnson S, et al:Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med, 341:1645-1651, 1999
PubMed
4) Aucoin P, et al:Clindamycin-induced cardiac arrest. South Med J, 75:768, 1982
PubMed
P.149 掲載の参考文献
1) Speer BS, et al:Bacterial resistance to tetracycline:mechanisms, transfer, and clinical significance. Clin Microbiol Rev, 5:387-399, 1992
PubMed
2) Minuth JN, et al:Activity of tetracycline, doxycycline, and minocycline against methicillin-susceptible and -resistant staphylococci. Antimicrob Agents Chemother, 6:411-414, 1974
PubMed
3) McTaggart LR, et al:Antimicrobial susceptibility among clinical Nocardia species identified by multilocus sequence analysis. Antimicrob Agents Chemother, 59:269-275, 2015
PubMed
4) Alhayani T, et al:Comparison of Doxycycline or Minocycline to Sulfamethoxazole-Trimethoprim for Treatment of Stenotrophomonas maltophilia Pneumonia. Ann Pharmacother, 26:10600280231166413, 2023
PubMed
5) Chen SC, et al:Antibiotic therapy for necrotizing fasciitis caused by Vibrio vulnificus:retrospective analysis of an 8 year period. J Antimicrob Chemother, 67:488-493, 2012
PubMed
6) Hand E, et al:Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J Antimicrob Chemother, 71:1071-1075, 2016
PubMed
P.153 掲載の参考文献
1) Nahar S, et al:Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol, 42:4856-4858, 2004
PubMed
P.156 掲載の参考文献
1) Paul M, et al:Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus:randomised controlled trial. BMJ, 350:h2219, 2015
PubMed
P.166 掲載の参考文献
1) Kim SH, et al:Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother, 52:192-197, 2008
PubMed
2) 「抗菌薬TDM臨床実践ガイドライン2022」(抗菌薬TDMガイドライン作成委員会/TDMガイドライン策定委員会抗菌薬小委員会/編), 日本化学療法学会/日本TDM学会, 2022
 
3) Hammond DA, et al:Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Clin Infect Dis, 64:666-674, 2017
PubMed
4) Lee CH, et al:Teicoplanin therapy for MRSA bacteraemia:a retrospective study emphasizing the importance of maintenance dosing in improving clinical outcomes. J Antimicrob Chemother, 70:257-263, 2015
PubMed
P.172 掲載の参考文献
1) Meka VG, et al:Antimicrobial resistance to linezolid. Clin Infect Dis, 39:1010-1015, 2004
PubMed
2) Abad L, et al:Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting. J Antimicrob Chemother, 74:625-632, 2019
PubMed
3) Watkins RR, et al:An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA):place in therapy. Core Evid, 7:131-143, 2012
PubMed
4) Wunderink RG, et al:Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia:a randomized, controlled study. Clin Infect Dis, 54:621-629, 2012
PubMed
5) Matsumoto K, et al:Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents, 36:179-181, 2010
PubMed
6) Mao Y, et al:The risk factors of linezolid-induced lactic acidosis:A case report and review. Medicine (Baltimore), 97:e12114, 2018
PubMed
P.176 掲載の参考文献
1) Humphries RM, et al:A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev, 26:759-780, 2013
PubMed
2) Seaton RA, et al:Evaluation of Effectiveness and Safety of High-Dose Daptomycin:Results from Patients Included in the European Cubicin(R) Outcomes Registry and Experience. Adv Ther, 32:1192-1205, 2015
 
3) Gomez EO, et al:Daptomycin and rifampin for the treatment of methicillin-resistant Staphylococcus aureus septic pulmonary emboli in the absence of endocarditis. Microb Drug Resist, 16:241-244, 2010
PubMed

第4章 抗真菌薬の使い方まとめてみました

P.195 掲載の参考文献
1) Pappas PG, et al:Clinical Practice Guideline for the Management of Candidiasis:2016 Update by the Infectious Diseases Society of America. Clin Infect Dis, 62:e1-50, 2016
 
2) Perfect JR, et al:Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of america. Clin Infect Dis, 50:291-322, 2010
 
3) Perreault S, et al:Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies. J Oncol Pharm Pract, 25:1305-1311, 2019
PubMed
4) Wong TY, et al:Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients:a systematic review with meta-analysis and trial sequential analysis. Sci Rep, 10:14575, 2020
PubMed
P.199 掲載の参考文献
1) Wiederhold NP:Antifungal Susceptibility Testing:A Primer for Clinicians. Open Forum Infect Dis, 8:ofab444, 2021
PubMed
2) Singh N, et al:Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients:a prospective, multicenter, observational study. Transplantation, 81:320-326, 2006
PubMed
P.203 掲載の参考文献
1) Carolus H, et al:Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance. J Fungi (Basel), 6:321, 2020
PubMed
2) Perfect JR, et al:Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of america. Clin Infect Dis, 50:291-322, 2010
 
3) Wright DG, et al:Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med, 304:1185-1189, 1981
PubMed

第5章 感染症ごとの使い方、考え方

P.209 掲載の参考文献
1) de Gans J, et al:Dexamethasone in adults with bacterial meningitis. N Engl J Med, 347:1549-1556, 2002
PubMed
P.213 掲載の参考文献
1) Hicks CW, et al:Identifying and managing intracranial complications of sinusitis in children:a retrospective series. Pediatr Infect Dis J, 30:222-226, 2011
PubMed
P.221 掲載の参考文献
1) Steyer TE:Peritonsillar abscess:diagnosis and treatment. Am Fam Physician, 65:93-96, 2002
PubMed
P.227 掲載の参考文献
1) Hageman JC, et al:Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis, 12:894-899, 2006
PubMed
2) 「飯塚イズムで学ぶ 流れがわかる! 感染症診療の歩きかた」(的野多加志/編), 南山堂, 2022
 
3) 「成人肺炎診療ガイドライン2017」(日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会/編), 日本呼吸器学会, 2017
 
4) 「成人市中肺炎診療ガイドライン」(日本呼吸器学会市中肺炎診療ガイドライン作成委員会/編), 日本呼吸器学会, 2006
 
P.233 掲載の参考文献
1) Mandell LA & Niederman MS:Aspiration Pneumonia. N Engl J Med, 380:651-663, 2019
PubMed
2) Wunderink RG:How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy? Infect Dis Clin North Am, 27:177-188, 2013
PubMed
3) [Antibiotic Essentials 2020] (Cunha CB & Cunha AC, eds), Jaypee Brothers Medical Publishers, 2020
 
P.238 掲載の参考文献
1) Miller WR, et al:Enterococcus Species, Streptococcus gallolyticus Group, and Leuconostoc Species. [Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed] (Bennett JE, et al), p2497, Elsevier, 2019
 
P.243 掲載の参考文献
1) Davis TK, et al:Treatment of Shiga toxin-producing Escherichia coli infections. Infect Dis Clin North Am, 27:577-597, 2013
PubMed
P.249 掲載の参考文献
1) Scott JH 3rd, et al:Abnormal urinalysis in appendicitis. J Urol, 129:1015, 1983
PubMed
2) Schuler F, et al:A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia. Open Forum Infect Dis, 8:ofab158, 2021
 
3) Miller WR, et al:Enterococcus Species, Streptococcus gallolyticus Group, and Leuconostoc Species. [Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed] (Bennett JE, et al), p2497, Elsevier, 2019
 
4) Gupta K, et al:International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women:A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis, 52:e103-e120, 2011
 
P.253 掲載の参考文献
1) Miller WC, et al:Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA, 291:2229-2236, 2004
PubMed
2) Dukers-Muijrers NHTM, et al:Treatment Effectiveness of Azithromycin and Doxycycline in Uncomplicated Rectal and Vaginal Chlamydia trachomatis Infections in Women:A Multicenter Observational Study (FemCure). Clin Infect Dis, 69:1946-1954, 2019
PubMed
3) Workowski KA, et al:Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep, 70:1-187, 2021
PubMed
P.258 掲載の参考文献
1) Macdonald KE, et al:The microbiology of diabetic foot infections:a meta-analysis. BMC Infect Dis, 21:770, 2021
PubMed
2) Ko LN, et al:Clinical Usefulness of Imaging and Blood Cultures in Cellulitis Evaluation. JAMA Intern Med, 178:994-996, 2018
PubMed
3) Wilkins AL, et al:Toxic shock syndrome - the seven Rs of management and treatment. J Infect, 74 Suppl 1:S147-S152, 2017
 
P.263 掲載の参考文献
1) Wong CH, et al:The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score:a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med, 32:1535-1541, 2004
 
2) Hua C, et al:Necrotising soft-tissue infections. Lancet Infect Dis, 23:e81-e94, 2023
PubMed
P.268 掲載の参考文献
1) Tande AJ & Patel R:Prosthetic joint infection. Clin Microbiol Rev, 27:302-345, 2014
PubMed
2) Wi YM & Patel R:Understanding Biofilms and Novel Approaches to the Diagnosis, Prevention, and Treatment of Medical Device-Associated Infections. Infect Dis Clin North Am, 32:915-929, 2018
 
P.276 掲載の参考文献
1) Li JS, et al:Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis, 30:633-638, 2000
 
2) Fowler VG, et al:The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis:Updating the Modified Duke Criteria. Clin Infect Dis, 77:518-526. 2023
PubMed
3) Marino A, et al:Ampicillin Plus Ceftriaxone Regimen against Enterococcus faecalis Endocarditis:A Literature Review. J Clin Med, 10:4594, 2021
PubMed
4) McDonald EG, et al:Guidelines for Diagnosis and Management of Infective Endocarditis in Adults:A WikiGuidelines Group Consensus Statement. JAMA Netw Open, 6:e2326366, 2023
PubMed
5) Lancashire J & Crowther M:Blood smear:fulminant pneumococcal bacteremia. Blood, 120:4459, 2012
PubMed
P.281 掲載の参考文献
1) Buetti N, et al:Local signs at insertion site and catheter-related bloodstream infections:an observational post hoc analysis using individual data of four RCTs. Crit Care, 24:694, 2020
PubMed
2) Fijan S & Turk SS:Hospital textiles, are they a possible vehicle for healthcare-associated infections? Int J Environ Res Public Health, 9:3330-3343, 2012
PubMed
3) Mermel LA, et al:Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection:2009 Update by the Infectious Diseases Society of America. Clin Infect Dis, 49:1-45, 2009
 

書評

最近チェックした商品履歴

Loading...